IRX5

Across TCGA pan-cancer cohorts, IRX5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IRX5 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher IRX5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRX5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, MESO, and BLCA are the cancer types where IRX5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.091	0.830	<.001	48	view →
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
BLCA	OS	Median	IV	0.153	0.609	<.001	12	view →
LIHC	DFS	Median	All	0.074	0.555	<.001	12	view →
KIRC	OS	Median	All	0.244	0.810	.008	6	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →
UCEC	DFS	Median	All	0.951	0.829	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IRX5–CESC (OS)

Open the CESC breakdown →